News
A recent dual-cohort study has found that Lupus Low Disease Activity State (LLDAS) is an attainable and effective treatment target for people with lupus nephritis (LN, lupus-related kidney disease).
The Lupus Foundation of America (LFA) and Lupus Canada are pleased to announce Mohamed Osman, MD, PhD, Associate Professor of ...
A new study found a high prevalence of chronic kidney disease (CKD) among people with systemic lupus erythematosus (SLE), ...
The Lupus & You: Empowerment conference is an experience that celebrates, inspires, supports, and uplifts lupus warriors, care partners, family, and friends. During this empowering day, attendees will ...
Cullinan Therapeutics has announced a licensing agreement with Genrix Bio for global rights to velinotamig, a clinical-stage BCMAxCD3 bispecific T cell engager.
This week, the American College of Rheumatology (ACR) released updated guidelines for the treatment and management of systemic lupus erythematosus (SLE), the most common form of lupus. The new ...
Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...
March is here, and as we observe Kidney Month, it’s crucial to raise awareness about how lupus can severely impact the kidneys.
The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene Therapeutics’ ALLO-329, an investigational allogenic CAR-T cell therapy.
Today at the American College of Rheumatology (ACR) Annual Meeting, Convergence 2024, the ACR released a summary of a new guideline for the screening, treatment and management of lupus nephritis ...
In a new study, researchers identify biomarkers that may predict the efficacy of low-dose IL-2 (Ld-IL2) treatment in people with systemic lupus erythematosus (SLE).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results